What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis?

In vitro and in vivo experimental data have pointed to new immunopathogenic mechanisms in primary Sjögren's syndrome (pSS). The availability of targeted treatment modalities has opened new ways to selectively target these mechanistic pathways in vivo. This has taught us that the role of proinfl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kallenberg, Cees GM, Vissink, Arjan, Kroese, Frans GM, Abdulahad, Wayel H, Bootsma, Hendrika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3157640/
https://www.ncbi.nlm.nih.gov/pubmed/21371351
http://dx.doi.org/10.1186/ar3234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3157640/
https://www.ncbi.nlm.nih.gov/pubmed/21371351
http://dx.doi.org/10.1186/ar3234

Ejemplares similares